Avicanna Secures Patent for Innovative Topical Cannabinoid Technology
Avicanna Announces Patent Issuance for Topical Technology
Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) has received a significant boost with the issuance of Patent No. US 20230025693A1 by the United States Patent and Trademark Office (“USPTO”). This patent covers Avicanna's innovative deep penetrating topical cannabinoid composition designed for treating musculoskeletal inflammation and pain.
Importance of the New Patent
“We are very happy with the issuance of another USPTO patent, this time on transdermal topical technology that has been a significant part of our research and development (R&D) and clinical efforts,” stated Aras Azadian, CEO of Avicanna. This breakthrough technology represents years of dedicated research, development, and trials, including AI-guided prediction modeling and real-world evidence.
Key advancements are expected as Avicanna continues to incorporate these patented technologies into its evolving product pipeline, particularly for addressing musculoskeletal pain and inflammation challenges effectively.
Benefits of Topical Formulations
While many medications are available to alleviate pain, they often produce unwanted side effects. Avicanna's topical formulations are potentially advantageous because they can deliver active ingredients directly into the tissue's deeper layers, enhancing effectiveness while reducing gastrointestinal, central nervous system, and cardiovascular side effects.
Evidence-Based Results
Extensive real-world evidence further validates the technology's efficacy. In a recent study involving seventy-one patients who reported symptoms associated with musculoskeletal pain and inflammation, participants completed two standardized symptom questionnaires. After one month of using the RHO Phyto CBG Transdermal Gel, which contains 2% cannabidiol and 1% Cannabigerol, many noted significant improvements in their quality of life and symptom management.
About Avicanna’s Advanced Technology
The technology behind Avicanna's transdermal products enhances the diffusion of cannabinoids through the skin's layers. This innovative approach incorporates cannabinoids within a specially designed nano- and micro-emulsion system, stabilized in a gel matrix with effective penetration enhancers. The patented water-based gel leverages Avicanna's deep tissue technology combined with synergistic terpenes and natural excipients.
Avicanna’s Commitment to Quality
Avicanna is dedicated to developing and commercializing cannabinoid-based products alongside extensive R&D capabilities. The company has introduced over thirty proprietary, evidence-based products, supporting their vision to lead in the global medical and pharmaceutical markets.
Overview of Avicanna's Product Range
Avicanna's medical cannabis formulary, RHO Phyto™, is known for its extensive array of proprietary products, including oral, sublingual, topical, and transdermal delivery systems with varying cannabinoid concentrations. RHO Phyto stands out as a leading medical brand, expanding its reach in international markets while maintaining a strong presence in Canada.
Innovative Health Solutions
The company also offers a sophisticated medical cannabis care platform named MyMedi.ca. This platform is designed to aid patients and improve their health journeys. MyMedi.ca operates under Northern Green Canada Inc. and provides a diverse portfolio of products alongside bilingual pharmacist-led support programs, catering to various patient needs.
Avicanna’s Future Prospects
Moreover, Avicanna’s pharmaceutical product line includes Trunerox™, which was recently approved as an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome. This approval reflects Avicanna's commitment to addressing unmet medical needs in neurology and chronic pain through scientific innovation.
Concluding Remarks
As Avicanna Inc. continues to navigate the evolving landscape of cannabinoid-based therapies, its newly acquired patent positions the company favorably. By leveraging its scientific expertise and established business pillars, Avicanna is poised for substantial advancements in the pharmaceutical domain of cannabinoid products.
Frequently Asked Questions
What is the new patent issued to Avicanna about?
The patent covers Avicanna’s deep penetrating topical cannabinoid composition aimed at treating musculoskeletal inflammation and pain.
How does Avicanna's topical technology work?
The technology is designed to enhance the transdermal delivery of cannabinoids, allowing for better penetration and efficacy while reducing systemic side effects.
What are the reported results from Avicanna’s clinical studies?
In clinical studies, participants using RHO Phyto CBG Transdermal Gel reported significant improvements in symptoms and quality of life related to musculoskeletal issues.
Where can Avicanna’s products be accessed?
Avicanna's RHO Phyto products are available nationwide in Canada and are gradually expanding into international markets.
What is Avicanna’s commitment to innovation?
Avicanna is committed to developing cannabinoid-based products backed by strong research and clinical evidence, addressing various medical needs across different specialties.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- DeepCure Showcases Powerful New Treatment for RA That Outshines Etanercept
- Unlocking Information Quality: A Symposium for Everyone
- Vir Biotechnology's Upcoming Engagements and Innovations in Healthcare
- The Growing IT Skills Gap: Insights for UK Businesses
- VyStar Credit Union Expands Workforce with New Opportunities
- Sustainability Education: A Must-Have for America’s Schools
- TMTG Faces Legal Challenges Amid Expansion Efforts
- Canadian Physician Consensus: Urgent Need for AI Regulations
- Alzamend Neuro Secures $6.5 Million Through ATM Offering
- Zyxel Launches Advanced Wi-Fi 7 Gateways for Service Providers
Recent Articles
- Cartier Resources Reports High-Grade Gold Intersections
- Abcourt Mines Reports High-Grade Gold Intersections
- Bread Financial™ to Engage at Barclays Financial Services Conference
- CERIS Innovations in Fraud Prevention Solutions
- Archrock Completes HSR Act Waiting Period for Acquisition
- SEALSQ Corp Innovations in Quantum-Resistant Digital Wallets
- Investing Insights into Berkshire Hathaway's Performance
- Investing in Current Stock Market Giants
- Ozempic's Impact on Novo Nordisk: Recent Findings
- Mural Oncology to Join Major Investor Conferences
- European Wax Center to Speak at Piper Sandler Conference
- EyePoint Pharmaceuticals Prepares for Investor Conferences
- Super Hi Reports Strong Q2 2024 Financial Results
- Invivyd's PEMGARDA™ Shows 84% Risk Reduction in COVID-19
- Supremex Launches First Environmental, Social and Governance Report
- Fox Factory's Commitment to Sustainability in 2023
- Clearside Biomedical Completes Final Participant Visit in ODYSSEY Trial
- Advancements in the Cosmetic Peptide Synthesis Market
- Vacuum Evaporation Boat Market Expected Growth to $4.1 Billion
- Skydance Media to Acquire Paramount Global Amid Bidding War
- Solar Coca-Cola Boosts Delivery Efficiency with Descartes
- Palo Alto Networks: AI and Cybersecurity Leadership
- Alliance Trust PLC Reports Latest Net Asset Value Insights
- Scotiabank Reports Drop in Q3 Profit Amid Credit Loss Provisions
- Iovance Biotherapeutics: A Path to Growth with Amtagvi
- Market Update: Investors Eye Nvidia's Earnings
- Aircraft Ground Support Equipment Market Growth Insights
- 3D Printing Glasses Market Growth Forecast
- Underground Mining Equipment Market Growth Forecast
- Laser Gas Analyzer Market Set to Reach $5.39 Billion by 2034
- Cheer Holding Secures Patent for AI Data Management System
- Parsons Announces Lead Engineering Role on Toll Lane Project
- Kronos Advanced Technologies to Acquire Suarez Corporation
- Disclosure of Interests by Rathbones Group Plc
- Key Disclosure by Rathbones Group Plc in Keywords Studios Plc
- Discover Wall Street's Top Dividend Stocks
- Top Stocks to Consider Ahead of Fed Rate Cuts
- Three AI Stocks Competing with Nvidia's Growth
- Epoxy Curing Agents Market Forecast to Reach USD 10.1 Billion
- Bitumen Market Projections: USD 116 Billion by 2034
- Toughened Glass Market Growth Forecast to Reach USD 94.6 Billion
- Calibre Enhances Gold Exploration Results at Pan Mine
- Jiayin Group Inc. Reports Strong Q2 2024 Financial Results
- Matrix Service Company Announces Fourth Quarter Financial Call
- Record High Household Debt in Canada: Insights and Implications
- LanzaTech's Upcoming Investor Events Engagement
- Liberty Bank, N.A. Opens New Branch in Millbrae Community
- JD.com Unveils $5 Billion Share Repurchase Initiative
- Elis Discloses Share Capital and Voting Rights Information
- Super Micro Computer's Growth Prospects Linked to Nvidia